Lifestyle habits and bladder cancer prognosis: effects by tumour stage and molecular subtype.
Non-muscle invasive bladder cancer patients (NMIBC) with T1 tumours or genomically unstable/squamous-cell-carcinoma-like molecular subtypes have a high risk of recurrence and muscle-invasive progression, the latter being a life-threatening condition. This project will provide insight in whether associations of smoking, body weight, physical activity, and fruit and vegetable consumption with NMIBC outcomes are mediated and/or modified by tumour stage and molecular subtype. Our ultimate aim is to provide NMIBC patients with tailored advice concerning their lifestyle to enable them to influence their prognosis.
Collaboration between Radboudumc (Project Leader Alina Vrieling, Principal Investigator Bart Kiemeney) and Erasmus MC (Principal Investigator Dr. Arno van Leenders)
Related news items
Large AI project receives over €95 million for ten years of public-private research23 September 2021
Radboud university medical center (Radboudumc) participates in the ROBUST consortium, which consists of 17 AI labs, eight of which are dedicated to healthcare. Radboud university medical center leads five of these eight labs.read more
Reading ADP-ribosylation signaling using chemical biology and interaction proteomics published in Molecular Cell22 September 2021
Kasia Kliza and Michiel Vermeulen worked on a project to synthesize biotinylated ADPr-based probes that can identify ADPr readers and determine their specificity for mono- and polyADPr. They published this in Molecular Cell.read more
Systematic analysis of short tandem repeats in 38,095 exomes provides an additional diagnostic yield22 September 2021
Christian Gilissen and colleagues published in Genetics in Medicine about their work guiding the application of short tandem repeat analysis in clinical exome sequencing.read more
New start-up Patholyt will bring AI research into pathology diagnostics21 September 2021
Patholyt is on a mission to accelerate the adoption of artificial intelligence in pathology diagnostics and improve the chances of cancer patients worldwide. Patholyt is a spin-off from Radboudumc, a frontrunner in computational pathology research.read more